SCHEMBL16748451

SCHEMBL16748451

Cc1nc2ncc(Cl)cc2n1-c1nc(N)nc(Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGPAT2 O15120 3/20 0.42
BMI1 P35226 5/20 0.42
CDK2 P24941 1/20 0.37
GSK3B P49841 1/20 0.37
APP P05067 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
FFAR1 O14842 1/20 0.35
KCNH2 Q12809 1/20 0.35
SCN9A Q15858 1/20 0.35
EGFR P00533 1/20 0.34
CYBB P04839 1/20 0.34
NOX5 Q96PH1 1/20 0.34
NOX3 Q9HBY0 1/20 0.34
NOX4 Q9NPH5 1/20 0.34
NOX1 Q9Y5S8 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740873 0.90 APP (0.44) AGPAT2BMI1CDK2GSK3BAPP
SCHEMBL16748492 0.90 BMI1 (0.50) AGPAT2BMI1CDK2GSK3BAPP
SCHEMBL16740815 0.89 BMI1 (0.42) AGPAT2BMI1CDK2GSK3BLMNA
SCHEMBL16748530 0.88 CHRNA7 (0.46) CTSSCTSKKCNH2SCN9A
SCHEMBL16748579 0.85 BMI1 (0.51) AGPAT2BMI1APPLMNAMAPT
SCHEMBL16740804 0.85 AGPAT2 (0.49) AGPAT2BMI1APPLMNAMAPT
SCHEMBL15742594 0.85 BMI1 (0.41) AGPAT2BMI1CDK2GSK3BTRPV1
SCHEMBL15742526 0.85 BMI1 (0.48) AGPAT2BMI1CDK2GSK3BTRPV1
SCHEMBL16541097 0.85 BMI1 (0.48) AGPAT2BMI1CDK2GSK3BAPP
SCHEMBL16748434 0.84 GBA1 (0.45) BMI1MAPTKCNH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B AGPAT2 3973/4885BMI1 1/4885CDK2 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.